Press releases
07 October 2026
Byondis to Profile Potential of Platform Technologies at World ADC San Diego, Advancing Strategy to Lead the Antibody-Drug Conjugate Field
Read more18 May 2026
Byondis Establishes Scientific Advisory Board of Recognized Leaders in Oncology Research and ADC Development
Read more17 April 2026
Byondis to Present Data from its Novel ADC Technology Platforms at the American Society for Cancer Research Meeting 2026
Read moreAbout Byondis
Driven to improve patients’ lives, Byondis is an independent, fully integrated biopharmaceutical research and development company creating innovative targeted medicines for cancer. The company is developing new biological entities (NBEs) with a focus on antibody-drug conjugates.
Byondis’ development portfolio leverages expertise in linker-drug (LD) technology, antibody-drug conjugation, and disease biology. Byondis’ fully integrated drug development capabilities cover all stages from pre-clinical and clinical R&D, production of clinical batches of the selected product candidates, and regulatory filings which are all done in-house.
The company has a dedicated team of more than 200 staff working in its state-of-the-art R&D and GMP manufacturing facilities in Nijmegen, the Netherlands.
R&D and Manufacturing
Fully integrated in-house R&D and Manufacturing from discovery to development to commercial supply.
Investors & Media
Byondis is an independent clinical stage fully integrated biopharmaceutical research and development company creating innovative targeted medicines for cancer. The company is developing new biological entities (NBEs) with a focus on antibody-drug conjugates and antibody-based therapeutics.
